Trial · NCT07886229
Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
NCT07886229, Phase 1, Recruiting, Second Xiangya Hospital of Central South University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer. Trials, record NCT07886229. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886229
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
- NCT number
- NCT07886229
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 9 participants, estimated
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Conditions
- Resectable Non-Small-Cell Lung Cancer
- Interventions
- Propranolol Hydrochloride, Toripalimab, Chemotherapy
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Dose-Limiting Toxicities (DLTs) | Day 1 through Day 21 | The number and percentage of participants experiencing dose-limiting toxicities at each propranolol dose level during the protocol-defined DLT assessment period. DLTs will be used to guide dose escalation in the conventional 3+3 design. |
| Primary | Incidence and Severity of Adverse Events (AEs) | Through study completion, up to 12 months | The number and percentage of participants experiencing adverse events (AEs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and immune-related adverse events (irAEs). Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. |
| Secondary | Recommended Phase II Dose (RP2D) of Propranolol | Through study completion, up to 12 months | The recommended Phase II dose of propranolol hydrochloride in combination with toripalimab and platinum-based doublet chemotherapy, determined based on the safety, tolerability, and DLT findings during Phase Ib dose escalation. |
| Secondary | Pathological Complete Response (pCR) Rate | Perioperative | The percentage of participants achieving pathological complete response, defined as the absence of residual viable tumor cells in both the primary tumor bed and sampled regional lymph nodes following neoadjuvant treatment, as determined by pathological examination of surgical specimens. |
| Secondary | Major Pathological Response (MPR) Rate | Perioperative | The percentage of participants achieving major pathological response, defined as 10% or less residual viable tumor cells in the primary tumor bed following neoadjuvant treatment, regardless of residual viable tumor cells in regional lymph nodes. |
| Secondary | Objective Response Rate (ORR) | Up to 6 months | The percentage of participants achieving a complete response (CR) or partial response (PR), as assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886229
GET https://conductscience.org/api/trials/v1/NCT07886229/registered